4,740 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by Profund Advisors LLC

Profund Advisors LLC acquired a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,740 shares of the company’s stock, valued at approximately $1,147,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ONC. Caitong International Asset Management Co. Ltd bought a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $28,000. Farther Finance Advisors LLC bought a new stake in BeOne Medicines during the 2nd quarter valued at $39,000. Signaturefd LLC purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth $49,000. Parallel Advisors LLC purchased a new position in shares of BeOne Medicines during the second quarter valued at $59,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of BeOne Medicines in the second quarter valued at about $121,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $343.65 on Wednesday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $170.99 and a 52 week high of $355.30. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The firm has a market cap of $37.68 billion, a P/E ratio of 673.82 and a beta of 0.31. The business’s 50 day moving average price is $327.61 and its 200 day moving average price is $289.50.

Insider Activity

In related news, CEO John Oyler sold 27,803 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total transaction of $9,055,715.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Lai Wang sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total transaction of $1,750,300.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 96,203 shares of company stock valued at $30,923,233 over the last quarter. Insiders own 6.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada boosted their price target on shares of BeOne Medicines from $374.00 to $395.00 and gave the company an “outperform” rating in a report on Friday, November 7th. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Barclays assumed coverage on shares of BeOne Medicines in a research report on Thursday, September 18th. They set an “overweight” rating and a $385.00 price target for the company. Finally, Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $357.33.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.